PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology

被引：12

作者：

Altschmiedova, Tereza ^{[1
]}

Todorovova, Veronika ^{[1
]}

Snejdrlova, Michaela ^{[1
]}

Satny, Martin ^{[1
]}

Ceska, Richard ^{[1
]}

机构：

[1] Charles Univ Prague, Gen Univ Hosp, Fac Med 1, Dept Internal Med,Ctr Prevent Cardiol, Prague, Czech Republic

来源：

CURRENT ATHEROSCLEROSIS REPORTS | 2022年 / 24卷 / 05期

关键词：

Atherosclerotic cardiovascular disease (ASCVD); LDL cholesterol; PCSK9; inhibitors; Alirocumab; Evolocumab; Real-world data (RWD); 9; SERINE-PROTEASE; LOW LDL; HYPERCHOLESTEROLEMIA; CHOLESTEROL;

D O I：

10.1007/s11883-022-01008-8

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Purpose of Review PCSK9 inhibitors have been shown to be the most effective class of drugs modifying the levels of LDL-cholesterol as the main risk factor for atherosclerotic cardiovascular disease. The aim of this paper is to assess the effect of monoclonal antibodies on lipid and lipoprotein metabolism in real-world practice. Recent Findings The outcome trials showed effective reduction of LDL-C by 56-62%. Landmark studies enrolling over a total of 46,000 patients with CHD in their medical history demonstrated the beneficial effect of both agents on cardiovascular morbidity and mortality. The data from real everyday clinical practice are very limited or missing. Even in real-world practice, PCSK9 inhibitors have been shown to be an effective, safe, and well-tolerated class of drugs with effects comparable with those reported from large randomized controlled trials.

引用

页码：357 / 363

页数：7

共 16 条

[1] State of secondary prevention in Czech coronary patients in the EUROASPIRE IV study [J].

Bruthans, Jan ;

Mayer, Otto, Jr. ;

Galovcova, Marketa ;

Seidlerova, Jitka ;

Belohoubek, Jiri ;

Timoracka, Katarina ;

Vagovicova, Petra ;

Adamkova, Vera ;

Vanek, Jiri ;

Filipovsky, Jan ;

Cifkova, Renata .

COR ET VASA, 2014, 56 (02) :E105-E112

[2] 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias [J].

Catapano, Alberico L. ;

Graham, Ian ;

De Backer, Guy ;

Wiklund, Olov ;

Chapman, M. John ;

Drexel, Heinz ;

Hoes, Arno W. ;

Jennings, Catriona S. ;

Landmesser, Ulf ;

Pedersen, Terje R. ;

Reiner, Zeljko ;

Riccardi, Gabriele ;

Taskinen, Marja-Riita ;

Tokgozoglu, Lale ;

Monique, W. M. ;

Verschuren, W. M. Monique ;

Vlachopoulos, Charalambos ;

Wood, David A. ;

Luis Zamorano, Jose .

EUROPEAN HEART JOURNAL, 2016, 37 (39) :2999-+

[3] Sequence variations in PCSK9, low LDL, and protection against coronary heart disease [J].

Cohen, JC ;

Boerwinkle, E ;

Mosley, TH ;

Hobbs, HH .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) :1264-1272

[4]

eska R., 2018, ATHEROREV, V3, P201

[5] Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 [J].

Jonathan, C ;

Pertsemlidis, A ;

Kotowski, IK ;

Graham, R ;

Christine, KG ;

Garcia, CK ;

Hobbs, HH .

NATURE GENETICS, 2005, 37 (02) :161-165

[6] The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis [J].

Lipinski, Michael J. ;

Benedetto, Umberto ;

Escarcega, Ricardo O. ;

Biondi-Zoccai, Giuseppe ;

Lhermusier, Thibault ;

Baker, Nevin C. ;

Torguson, Rebecca ;

Brewer, H. Bryan, Jr. ;

Waksman, Ron .

EUROPEAN HEART JOURNAL, 2016, 37 (06) :536-U103

[7] 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (vol 41, pg 111, 2019) [J].

Mach, F. .

EUROPEAN HEART JOURNAL, 2020, 41 (44) :4255-4255

[8] 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) [J].

Mach, Francois ;

Baigent, Colin ;

Catapano, Alberico L. ;

Koskinas, Konstantinos C. ;

Casula, Manuela ;

Badimon, Lina ;

Chapman, M. John ;

De Backer, Guy G. ;

Delgado, Victoria ;

Ference, Brian A. ;

Graham, Ian M. ;

Halliday, Alison ;

Landmesser, Ulf ;

Mihaylova, Borislava ;

Pedersen, Terje R. ;

Riccardi, Gabriele ;

Richter, Dimitrios J. ;

Sabatine, Marc S. ;

Taskinen, Marja-Riitta ;

Tokgozoglu, Lale ;

Wiklund, Olov ;

Mueller, Christian ;

Drexel, Heinz ;

Aboyans, Victor ;

Corsini, Alberto ;

Doehner, Wolfram ;

Farnier, Michel ;

Gigante, Bruna ;

Kayikcioglu, Meral ;

Krstacic, Goran ;

Lambrinou, Ekaterini ;

Lewis, Basil S. ;

Masip, Josep ;

Moulin, Philippe ;

Petersen, Steffen ;

Petronio, Anna Sonia ;

Piepoli, Massimo Francesco ;

Pinto, Xavier ;

Raber, Lorenz ;

Ray, Kausik K. ;

Reiner, Zeljko ;

Riesen, Walter F. ;

Roffi, Marco ;

Schmid, Jean-Paul ;

Shlyakhto, Evgeny ;

Simpson, Iain A. ;

Stroes, Erik ;

Sudano, Isabella ;

Tselepis, Alexandros D. ;

Viigimaa, Margus .

EUROPEAN HEART JOURNAL, 2020, 41 (01) :111-188

[9] Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia A Systematic Review and Meta-analysis [J].

Navarese, Eliano Pio ;

Kolodziejczak, Michalina ;

Schulze, Volker ;

Gurbel, Paul A. ;

Tantry, Udaya ;

Lin, Yingfeng ;

Brockmeyer, Maximilian ;

Kandzari, David E. ;

Kubica, Julia M. ;

D'Agostino, Ralph B., Sr. ;

Kubica, Jacek ;

Volpe, Massimo ;

Agewall, Stefan ;

Kereiakes, Dean J. ;

Kelm, Melte .

ANNALS OF INTERNAL MEDICINE, 2015, 163 (01) :40-51

[10] Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation EVIDENCE FOR AN INTRACELLULAR ROUTE [J].

Poirier, Steve ;

Mayer, Gaetan ;

Poupon, Viviane ;

McPherson, Peter S. ;

Desjardins, Roxane ;

Ly, Kevin ;

Asselin, Marie-Claude ;

Day, Robert ;

Duclos, Franck J. ;

Witmer, Mark ;

Parker, Rex ;

Prat, Annik ;

Seidah, Nabil G. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (42) :28856-28864

← 1 2 →